Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin
The aim of the study was to assess the possibility of fixed combination Lisinopril + amlodipine + rozuvastatin to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous diuretic-based combination antihypertensive therapy. Materials and methods. In an...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
S V Nedogoda [verfasserIn] E V Chumachek [verfasserIn] A A Ledyaeva [verfasserIn] V V Tsoma [verfasserIn] A S Salasyuk [verfasserIn] V O Smirnova [verfasserIn] V Yu Khripaeva [verfasserIn] R V Palashkin [verfasserIn] E A Popova [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Russisch |
| Erschienen: |
2018 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
In: Системные гипертензии - IP Morozov P.V., 2018, 15(2018), 2, Seite 24-31 |
|---|---|
| Übergeordnetes Werk: |
volume:15 ; year:2018 ; number:2 ; pages:24-31 |
| Links: |
Link aufrufen |
|---|
| DOI / URN: |
10.26442/2075-082X_2018.2.24-31 |
|---|
| Katalog-ID: |
DOAJ07143416X |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | DOAJ07143416X | ||
| 003 | DE-627 | ||
| 005 | 20230309101723.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 230228s2018 xx |||||o 00| ||rus c | ||
| 024 | 7 | |a 10.26442/2075-082X_2018.2.24-31 |2 doi | |
| 035 | |a (DE-627)DOAJ07143416X | ||
| 035 | |a (DE-599)DOAJ99a27042b02c472cb25c448759d04427 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a rus | ||
| 050 | 0 | |a RC666-701 | |
| 100 | 0 | |a S V Nedogoda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin |
| 264 | 1 | |c 2018 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a The aim of the study was to assess the possibility of fixed combination Lisinopril + amlodipine + rozuvastatin to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous diuretic-based combination antihypertensive therapy. Materials and methods. In an open, observational study duration of 24 weeks was included 60 patients on previous diuretic-based combination antihypertensive therapy. All participants underwent 24-hour blood pressure monitoring, applanation tonometry (augmentation index and central blood pressure), pulse wave velocity measurement, laboratory tests (lipid profile, fasting glucose, insulin resistance index - NOMA), leptin, high-sensitivity C-reactive protein before and after the switching to a fixed combination of lisinopril + amlodipine + rosuvastatin. Results. According to measurements of office blood pressure switching of patients on double combinations based on diuretics to a fixed combination of lisinopril + amlodipine + rosuvastatin, a further decrease in systolic blood pressure (SBP) by 13.7% and diastolic BP (DBP) by 18.8% was observed. According to the ABPM, the decline in the average daily SBP was 15.8%, DBP - 22.5%, average SBP - 16.2%, DBP - 19.8%. The combination of lisinopril + amlodipine + rosuvastatin reduced PWV by 15.9%, augmentation index by 13.5%, central SBP by 8.4% (p | ||
| 650 | 4 | |a arterial hypertension | |
| 650 | 4 | |a pulse wave velocity | |
| 650 | 4 | |a central blood pressure | |
| 650 | 4 | |a augmentation index | |
| 650 | 4 | |a leptin | |
| 650 | 4 | |a inflammation | |
| 650 | 4 | |a indapamide | |
| 650 | 4 | |a hydrochlorothiazide | |
| 650 | 4 | |a lisinopril | |
| 650 | 4 | |a amlodipine | |
| 650 | 4 | |a rosuvastatin | |
| 653 | 0 | |a Diseases of the circulatory (Cardiovascular) system | |
| 700 | 0 | |a E V Chumachek |e verfasserin |4 aut | |
| 700 | 0 | |a A A Ledyaeva |e verfasserin |4 aut | |
| 700 | 0 | |a V V Tsoma |e verfasserin |4 aut | |
| 700 | 0 | |a A S Salasyuk |e verfasserin |4 aut | |
| 700 | 0 | |a V O Smirnova |e verfasserin |4 aut | |
| 700 | 0 | |a V Yu Khripaeva |e verfasserin |4 aut | |
| 700 | 0 | |a R V Palashkin |e verfasserin |4 aut | |
| 700 | 0 | |a E A Popova |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i In |t Системные гипертензии |d IP Morozov P.V., 2018 |g 15(2018), 2, Seite 24-31 |w (DE-627)1760597511 |x 25422189 |7 nnns |
| 773 | 1 | 8 | |g volume:15 |g year:2018 |g number:2 |g pages:24-31 |
| 856 | 4 | 0 | |u https://doi.org/10.26442/2075-082X_2018.2.24-31 |z kostenfrei |
| 856 | 4 | 0 | |u https://doaj.org/article/99a27042b02c472cb25c448759d04427 |z kostenfrei |
| 856 | 4 | 0 | |u https://syst-hypertension.ru/2075-082X/article/viewFile/29600/pdf |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2075-082X |y Journal toc |z kostenfrei |
| 856 | 4 | 2 | |u https://doaj.org/toc/2542-2189 |y Journal toc |z kostenfrei |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_DOAJ | ||
| 951 | |a AR | ||
| 952 | |d 15 |j 2018 |e 2 |h 24-31 | ||
| author_variant |
s v n svn e v c evc a a l aal v v t vvt a s s ass v o s vos v y k vyk r v p rvp e a p eap |
|---|---|
| matchkey_str |
article:25422189:2018----::mrvnbodrsueotoognpoetoadeaoidsresorcinnainsihyetninwthnfodueibsdobntos |
| hierarchy_sort_str |
2018 |
| callnumber-subject-code |
RC |
| publishDate |
2018 |
| allfields |
10.26442/2075-082X_2018.2.24-31 doi (DE-627)DOAJ07143416X (DE-599)DOAJ99a27042b02c472cb25c448759d04427 DE-627 ger DE-627 rakwb rus RC666-701 S V Nedogoda verfasserin aut Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The aim of the study was to assess the possibility of fixed combination Lisinopril + amlodipine + rozuvastatin to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous diuretic-based combination antihypertensive therapy. Materials and methods. In an open, observational study duration of 24 weeks was included 60 patients on previous diuretic-based combination antihypertensive therapy. All participants underwent 24-hour blood pressure monitoring, applanation tonometry (augmentation index and central blood pressure), pulse wave velocity measurement, laboratory tests (lipid profile, fasting glucose, insulin resistance index - NOMA), leptin, high-sensitivity C-reactive protein before and after the switching to a fixed combination of lisinopril + amlodipine + rosuvastatin. Results. According to measurements of office blood pressure switching of patients on double combinations based on diuretics to a fixed combination of lisinopril + amlodipine + rosuvastatin, a further decrease in systolic blood pressure (SBP) by 13.7% and diastolic BP (DBP) by 18.8% was observed. According to the ABPM, the decline in the average daily SBP was 15.8%, DBP - 22.5%, average SBP - 16.2%, DBP - 19.8%. The combination of lisinopril + amlodipine + rosuvastatin reduced PWV by 15.9%, augmentation index by 13.5%, central SBP by 8.4% (p arterial hypertension pulse wave velocity central blood pressure augmentation index leptin inflammation indapamide hydrochlorothiazide lisinopril amlodipine rosuvastatin Diseases of the circulatory (Cardiovascular) system E V Chumachek verfasserin aut A A Ledyaeva verfasserin aut V V Tsoma verfasserin aut A S Salasyuk verfasserin aut V O Smirnova verfasserin aut V Yu Khripaeva verfasserin aut R V Palashkin verfasserin aut E A Popova verfasserin aut In Системные гипертензии IP Morozov P.V., 2018 15(2018), 2, Seite 24-31 (DE-627)1760597511 25422189 nnns volume:15 year:2018 number:2 pages:24-31 https://doi.org/10.26442/2075-082X_2018.2.24-31 kostenfrei https://doaj.org/article/99a27042b02c472cb25c448759d04427 kostenfrei https://syst-hypertension.ru/2075-082X/article/viewFile/29600/pdf kostenfrei https://doaj.org/toc/2075-082X Journal toc kostenfrei https://doaj.org/toc/2542-2189 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 15 2018 2 24-31 |
| spelling |
10.26442/2075-082X_2018.2.24-31 doi (DE-627)DOAJ07143416X (DE-599)DOAJ99a27042b02c472cb25c448759d04427 DE-627 ger DE-627 rakwb rus RC666-701 S V Nedogoda verfasserin aut Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The aim of the study was to assess the possibility of fixed combination Lisinopril + amlodipine + rozuvastatin to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous diuretic-based combination antihypertensive therapy. Materials and methods. In an open, observational study duration of 24 weeks was included 60 patients on previous diuretic-based combination antihypertensive therapy. All participants underwent 24-hour blood pressure monitoring, applanation tonometry (augmentation index and central blood pressure), pulse wave velocity measurement, laboratory tests (lipid profile, fasting glucose, insulin resistance index - NOMA), leptin, high-sensitivity C-reactive protein before and after the switching to a fixed combination of lisinopril + amlodipine + rosuvastatin. Results. According to measurements of office blood pressure switching of patients on double combinations based on diuretics to a fixed combination of lisinopril + amlodipine + rosuvastatin, a further decrease in systolic blood pressure (SBP) by 13.7% and diastolic BP (DBP) by 18.8% was observed. According to the ABPM, the decline in the average daily SBP was 15.8%, DBP - 22.5%, average SBP - 16.2%, DBP - 19.8%. The combination of lisinopril + amlodipine + rosuvastatin reduced PWV by 15.9%, augmentation index by 13.5%, central SBP by 8.4% (p arterial hypertension pulse wave velocity central blood pressure augmentation index leptin inflammation indapamide hydrochlorothiazide lisinopril amlodipine rosuvastatin Diseases of the circulatory (Cardiovascular) system E V Chumachek verfasserin aut A A Ledyaeva verfasserin aut V V Tsoma verfasserin aut A S Salasyuk verfasserin aut V O Smirnova verfasserin aut V Yu Khripaeva verfasserin aut R V Palashkin verfasserin aut E A Popova verfasserin aut In Системные гипертензии IP Morozov P.V., 2018 15(2018), 2, Seite 24-31 (DE-627)1760597511 25422189 nnns volume:15 year:2018 number:2 pages:24-31 https://doi.org/10.26442/2075-082X_2018.2.24-31 kostenfrei https://doaj.org/article/99a27042b02c472cb25c448759d04427 kostenfrei https://syst-hypertension.ru/2075-082X/article/viewFile/29600/pdf kostenfrei https://doaj.org/toc/2075-082X Journal toc kostenfrei https://doaj.org/toc/2542-2189 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 15 2018 2 24-31 |
| allfields_unstemmed |
10.26442/2075-082X_2018.2.24-31 doi (DE-627)DOAJ07143416X (DE-599)DOAJ99a27042b02c472cb25c448759d04427 DE-627 ger DE-627 rakwb rus RC666-701 S V Nedogoda verfasserin aut Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The aim of the study was to assess the possibility of fixed combination Lisinopril + amlodipine + rozuvastatin to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous diuretic-based combination antihypertensive therapy. Materials and methods. In an open, observational study duration of 24 weeks was included 60 patients on previous diuretic-based combination antihypertensive therapy. All participants underwent 24-hour blood pressure monitoring, applanation tonometry (augmentation index and central blood pressure), pulse wave velocity measurement, laboratory tests (lipid profile, fasting glucose, insulin resistance index - NOMA), leptin, high-sensitivity C-reactive protein before and after the switching to a fixed combination of lisinopril + amlodipine + rosuvastatin. Results. According to measurements of office blood pressure switching of patients on double combinations based on diuretics to a fixed combination of lisinopril + amlodipine + rosuvastatin, a further decrease in systolic blood pressure (SBP) by 13.7% and diastolic BP (DBP) by 18.8% was observed. According to the ABPM, the decline in the average daily SBP was 15.8%, DBP - 22.5%, average SBP - 16.2%, DBP - 19.8%. The combination of lisinopril + amlodipine + rosuvastatin reduced PWV by 15.9%, augmentation index by 13.5%, central SBP by 8.4% (p arterial hypertension pulse wave velocity central blood pressure augmentation index leptin inflammation indapamide hydrochlorothiazide lisinopril amlodipine rosuvastatin Diseases of the circulatory (Cardiovascular) system E V Chumachek verfasserin aut A A Ledyaeva verfasserin aut V V Tsoma verfasserin aut A S Salasyuk verfasserin aut V O Smirnova verfasserin aut V Yu Khripaeva verfasserin aut R V Palashkin verfasserin aut E A Popova verfasserin aut In Системные гипертензии IP Morozov P.V., 2018 15(2018), 2, Seite 24-31 (DE-627)1760597511 25422189 nnns volume:15 year:2018 number:2 pages:24-31 https://doi.org/10.26442/2075-082X_2018.2.24-31 kostenfrei https://doaj.org/article/99a27042b02c472cb25c448759d04427 kostenfrei https://syst-hypertension.ru/2075-082X/article/viewFile/29600/pdf kostenfrei https://doaj.org/toc/2075-082X Journal toc kostenfrei https://doaj.org/toc/2542-2189 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 15 2018 2 24-31 |
| allfieldsGer |
10.26442/2075-082X_2018.2.24-31 doi (DE-627)DOAJ07143416X (DE-599)DOAJ99a27042b02c472cb25c448759d04427 DE-627 ger DE-627 rakwb rus RC666-701 S V Nedogoda verfasserin aut Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The aim of the study was to assess the possibility of fixed combination Lisinopril + amlodipine + rozuvastatin to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous diuretic-based combination antihypertensive therapy. Materials and methods. In an open, observational study duration of 24 weeks was included 60 patients on previous diuretic-based combination antihypertensive therapy. All participants underwent 24-hour blood pressure monitoring, applanation tonometry (augmentation index and central blood pressure), pulse wave velocity measurement, laboratory tests (lipid profile, fasting glucose, insulin resistance index - NOMA), leptin, high-sensitivity C-reactive protein before and after the switching to a fixed combination of lisinopril + amlodipine + rosuvastatin. Results. According to measurements of office blood pressure switching of patients on double combinations based on diuretics to a fixed combination of lisinopril + amlodipine + rosuvastatin, a further decrease in systolic blood pressure (SBP) by 13.7% and diastolic BP (DBP) by 18.8% was observed. According to the ABPM, the decline in the average daily SBP was 15.8%, DBP - 22.5%, average SBP - 16.2%, DBP - 19.8%. The combination of lisinopril + amlodipine + rosuvastatin reduced PWV by 15.9%, augmentation index by 13.5%, central SBP by 8.4% (p arterial hypertension pulse wave velocity central blood pressure augmentation index leptin inflammation indapamide hydrochlorothiazide lisinopril amlodipine rosuvastatin Diseases of the circulatory (Cardiovascular) system E V Chumachek verfasserin aut A A Ledyaeva verfasserin aut V V Tsoma verfasserin aut A S Salasyuk verfasserin aut V O Smirnova verfasserin aut V Yu Khripaeva verfasserin aut R V Palashkin verfasserin aut E A Popova verfasserin aut In Системные гипертензии IP Morozov P.V., 2018 15(2018), 2, Seite 24-31 (DE-627)1760597511 25422189 nnns volume:15 year:2018 number:2 pages:24-31 https://doi.org/10.26442/2075-082X_2018.2.24-31 kostenfrei https://doaj.org/article/99a27042b02c472cb25c448759d04427 kostenfrei https://syst-hypertension.ru/2075-082X/article/viewFile/29600/pdf kostenfrei https://doaj.org/toc/2075-082X Journal toc kostenfrei https://doaj.org/toc/2542-2189 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 15 2018 2 24-31 |
| allfieldsSound |
10.26442/2075-082X_2018.2.24-31 doi (DE-627)DOAJ07143416X (DE-599)DOAJ99a27042b02c472cb25c448759d04427 DE-627 ger DE-627 rakwb rus RC666-701 S V Nedogoda verfasserin aut Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin 2018 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier The aim of the study was to assess the possibility of fixed combination Lisinopril + amlodipine + rozuvastatin to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous diuretic-based combination antihypertensive therapy. Materials and methods. In an open, observational study duration of 24 weeks was included 60 patients on previous diuretic-based combination antihypertensive therapy. All participants underwent 24-hour blood pressure monitoring, applanation tonometry (augmentation index and central blood pressure), pulse wave velocity measurement, laboratory tests (lipid profile, fasting glucose, insulin resistance index - NOMA), leptin, high-sensitivity C-reactive protein before and after the switching to a fixed combination of lisinopril + amlodipine + rosuvastatin. Results. According to measurements of office blood pressure switching of patients on double combinations based on diuretics to a fixed combination of lisinopril + amlodipine + rosuvastatin, a further decrease in systolic blood pressure (SBP) by 13.7% and diastolic BP (DBP) by 18.8% was observed. According to the ABPM, the decline in the average daily SBP was 15.8%, DBP - 22.5%, average SBP - 16.2%, DBP - 19.8%. The combination of lisinopril + amlodipine + rosuvastatin reduced PWV by 15.9%, augmentation index by 13.5%, central SBP by 8.4% (p arterial hypertension pulse wave velocity central blood pressure augmentation index leptin inflammation indapamide hydrochlorothiazide lisinopril amlodipine rosuvastatin Diseases of the circulatory (Cardiovascular) system E V Chumachek verfasserin aut A A Ledyaeva verfasserin aut V V Tsoma verfasserin aut A S Salasyuk verfasserin aut V O Smirnova verfasserin aut V Yu Khripaeva verfasserin aut R V Palashkin verfasserin aut E A Popova verfasserin aut In Системные гипертензии IP Morozov P.V., 2018 15(2018), 2, Seite 24-31 (DE-627)1760597511 25422189 nnns volume:15 year:2018 number:2 pages:24-31 https://doi.org/10.26442/2075-082X_2018.2.24-31 kostenfrei https://doaj.org/article/99a27042b02c472cb25c448759d04427 kostenfrei https://syst-hypertension.ru/2075-082X/article/viewFile/29600/pdf kostenfrei https://doaj.org/toc/2075-082X Journal toc kostenfrei https://doaj.org/toc/2542-2189 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ AR 15 2018 2 24-31 |
| language |
Russian |
| source |
In Системные гипертензии 15(2018), 2, Seite 24-31 volume:15 year:2018 number:2 pages:24-31 |
| sourceStr |
In Системные гипертензии 15(2018), 2, Seite 24-31 volume:15 year:2018 number:2 pages:24-31 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
arterial hypertension pulse wave velocity central blood pressure augmentation index leptin inflammation indapamide hydrochlorothiazide lisinopril amlodipine rosuvastatin Diseases of the circulatory (Cardiovascular) system |
| isfreeaccess_bool |
true |
| container_title |
Системные гипертензии |
| authorswithroles_txt_mv |
S V Nedogoda @@aut@@ E V Chumachek @@aut@@ A A Ledyaeva @@aut@@ V V Tsoma @@aut@@ A S Salasyuk @@aut@@ V O Smirnova @@aut@@ V Yu Khripaeva @@aut@@ R V Palashkin @@aut@@ E A Popova @@aut@@ |
| publishDateDaySort_date |
2018-01-01T00:00:00Z |
| hierarchy_top_id |
1760597511 |
| id |
DOAJ07143416X |
| language_de |
russisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ07143416X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309101723.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2018 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.26442/2075-082X_2018.2.24-31</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ07143416X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ99a27042b02c472cb25c448759d04427</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">S V Nedogoda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The aim of the study was to assess the possibility of fixed combination Lisinopril + amlodipine + rozuvastatin to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous diuretic-based combination antihypertensive therapy. Materials and methods. In an open, observational study duration of 24 weeks was included 60 patients on previous diuretic-based combination antihypertensive therapy. All participants underwent 24-hour blood pressure monitoring, applanation tonometry (augmentation index and central blood pressure), pulse wave velocity measurement, laboratory tests (lipid profile, fasting glucose, insulin resistance index - NOMA), leptin, high-sensitivity C-reactive protein before and after the switching to a fixed combination of lisinopril + amlodipine + rosuvastatin. Results. According to measurements of office blood pressure switching of patients on double combinations based on diuretics to a fixed combination of lisinopril + amlodipine + rosuvastatin, a further decrease in systolic blood pressure (SBP) by 13.7% and diastolic BP (DBP) by 18.8% was observed. According to the ABPM, the decline in the average daily SBP was 15.8%, DBP - 22.5%, average SBP - 16.2%, DBP - 19.8%. The combination of lisinopril + amlodipine + rosuvastatin reduced PWV by 15.9%, augmentation index by 13.5%, central SBP by 8.4% (p</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">arterial hypertension</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pulse wave velocity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">central blood pressure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">augmentation index</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">leptin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">inflammation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">indapamide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hydrochlorothiazide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lisinopril</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">amlodipine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">rosuvastatin</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E V Chumachek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A A Ledyaeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V V Tsoma</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A S Salasyuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V O Smirnova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V Yu Khripaeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">R V Palashkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E A Popova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Системные гипертензии</subfield><subfield code="d">IP Morozov P.V., 2018</subfield><subfield code="g">15(2018), 2, Seite 24-31</subfield><subfield code="w">(DE-627)1760597511</subfield><subfield code="x">25422189</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:24-31</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.26442/2075-082X_2018.2.24-31</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/99a27042b02c472cb25c448759d04427</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://syst-hypertension.ru/2075-082X/article/viewFile/29600/pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2075-082X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2542-2189</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2018</subfield><subfield code="e">2</subfield><subfield code="h">24-31</subfield></datafield></record></collection>
|
| callnumber-first |
R - Medicine |
| author |
S V Nedogoda |
| spellingShingle |
S V Nedogoda misc RC666-701 misc arterial hypertension misc pulse wave velocity misc central blood pressure misc augmentation index misc leptin misc inflammation misc indapamide misc hydrochlorothiazide misc lisinopril misc amlodipine misc rosuvastatin misc Diseases of the circulatory (Cardiovascular) system Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin |
| authorStr |
S V Nedogoda |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1760597511 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut aut aut aut |
| collection |
DOAJ |
| remote_str |
true |
| callnumber-label |
RC666-701 |
| illustrated |
Not Illustrated |
| issn |
25422189 |
| topic_title |
RC666-701 Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin arterial hypertension pulse wave velocity central blood pressure augmentation index leptin inflammation indapamide hydrochlorothiazide lisinopril amlodipine rosuvastatin |
| topic |
misc RC666-701 misc arterial hypertension misc pulse wave velocity misc central blood pressure misc augmentation index misc leptin misc inflammation misc indapamide misc hydrochlorothiazide misc lisinopril misc amlodipine misc rosuvastatin misc Diseases of the circulatory (Cardiovascular) system |
| topic_unstemmed |
misc RC666-701 misc arterial hypertension misc pulse wave velocity misc central blood pressure misc augmentation index misc leptin misc inflammation misc indapamide misc hydrochlorothiazide misc lisinopril misc amlodipine misc rosuvastatin misc Diseases of the circulatory (Cardiovascular) system |
| topic_browse |
misc RC666-701 misc arterial hypertension misc pulse wave velocity misc central blood pressure misc augmentation index misc leptin misc inflammation misc indapamide misc hydrochlorothiazide misc lisinopril misc amlodipine misc rosuvastatin misc Diseases of the circulatory (Cardiovascular) system |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Системные гипертензии |
| hierarchy_parent_id |
1760597511 |
| hierarchy_top_title |
Системные гипертензии |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1760597511 |
| title |
Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin |
| ctrlnum |
(DE-627)DOAJ07143416X (DE-599)DOAJ99a27042b02c472cb25c448759d04427 |
| title_full |
Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin |
| author_sort |
S V Nedogoda |
| journal |
Системные гипертензии |
| journalStr |
Системные гипертензии |
| callnumber-first-code |
R |
| lang_code |
rus |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2018 |
| contenttype_str_mv |
txt |
| container_start_page |
24 |
| author_browse |
S V Nedogoda E V Chumachek A A Ledyaeva V V Tsoma A S Salasyuk V O Smirnova V Yu Khripaeva R V Palashkin E A Popova |
| container_volume |
15 |
| class |
RC666-701 |
| format_se |
Elektronische Aufsätze |
| author-letter |
S V Nedogoda |
| doi_str_mv |
10.26442/2075-082X_2018.2.24-31 |
| author2-role |
verfasserin |
| title_sort |
improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin |
| callnumber |
RC666-701 |
| title_auth |
Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin |
| abstract |
The aim of the study was to assess the possibility of fixed combination Lisinopril + amlodipine + rozuvastatin to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous diuretic-based combination antihypertensive therapy. Materials and methods. In an open, observational study duration of 24 weeks was included 60 patients on previous diuretic-based combination antihypertensive therapy. All participants underwent 24-hour blood pressure monitoring, applanation tonometry (augmentation index and central blood pressure), pulse wave velocity measurement, laboratory tests (lipid profile, fasting glucose, insulin resistance index - NOMA), leptin, high-sensitivity C-reactive protein before and after the switching to a fixed combination of lisinopril + amlodipine + rosuvastatin. Results. According to measurements of office blood pressure switching of patients on double combinations based on diuretics to a fixed combination of lisinopril + amlodipine + rosuvastatin, a further decrease in systolic blood pressure (SBP) by 13.7% and diastolic BP (DBP) by 18.8% was observed. According to the ABPM, the decline in the average daily SBP was 15.8%, DBP - 22.5%, average SBP - 16.2%, DBP - 19.8%. The combination of lisinopril + amlodipine + rosuvastatin reduced PWV by 15.9%, augmentation index by 13.5%, central SBP by 8.4% (p |
| abstractGer |
The aim of the study was to assess the possibility of fixed combination Lisinopril + amlodipine + rozuvastatin to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous diuretic-based combination antihypertensive therapy. Materials and methods. In an open, observational study duration of 24 weeks was included 60 patients on previous diuretic-based combination antihypertensive therapy. All participants underwent 24-hour blood pressure monitoring, applanation tonometry (augmentation index and central blood pressure), pulse wave velocity measurement, laboratory tests (lipid profile, fasting glucose, insulin resistance index - NOMA), leptin, high-sensitivity C-reactive protein before and after the switching to a fixed combination of lisinopril + amlodipine + rosuvastatin. Results. According to measurements of office blood pressure switching of patients on double combinations based on diuretics to a fixed combination of lisinopril + amlodipine + rosuvastatin, a further decrease in systolic blood pressure (SBP) by 13.7% and diastolic BP (DBP) by 18.8% was observed. According to the ABPM, the decline in the average daily SBP was 15.8%, DBP - 22.5%, average SBP - 16.2%, DBP - 19.8%. The combination of lisinopril + amlodipine + rosuvastatin reduced PWV by 15.9%, augmentation index by 13.5%, central SBP by 8.4% (p |
| abstract_unstemmed |
The aim of the study was to assess the possibility of fixed combination Lisinopril + amlodipine + rozuvastatin to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous diuretic-based combination antihypertensive therapy. Materials and methods. In an open, observational study duration of 24 weeks was included 60 patients on previous diuretic-based combination antihypertensive therapy. All participants underwent 24-hour blood pressure monitoring, applanation tonometry (augmentation index and central blood pressure), pulse wave velocity measurement, laboratory tests (lipid profile, fasting glucose, insulin resistance index - NOMA), leptin, high-sensitivity C-reactive protein before and after the switching to a fixed combination of lisinopril + amlodipine + rosuvastatin. Results. According to measurements of office blood pressure switching of patients on double combinations based on diuretics to a fixed combination of lisinopril + amlodipine + rosuvastatin, a further decrease in systolic blood pressure (SBP) by 13.7% and diastolic BP (DBP) by 18.8% was observed. According to the ABPM, the decline in the average daily SBP was 15.8%, DBP - 22.5%, average SBP - 16.2%, DBP - 19.8%. The combination of lisinopril + amlodipine + rosuvastatin reduced PWV by 15.9%, augmentation index by 13.5%, central SBP by 8.4% (p |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ |
| container_issue |
2 |
| title_short |
Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin |
| url |
https://doi.org/10.26442/2075-082X_2018.2.24-31 https://doaj.org/article/99a27042b02c472cb25c448759d04427 https://syst-hypertension.ru/2075-082X/article/viewFile/29600/pdf https://doaj.org/toc/2075-082X https://doaj.org/toc/2542-2189 |
| remote_bool |
true |
| author2 |
E V Chumachek A A Ledyaeva V V Tsoma A S Salasyuk V O Smirnova V Yu Khripaeva R V Palashkin E A Popova |
| author2Str |
E V Chumachek A A Ledyaeva V V Tsoma A S Salasyuk V O Smirnova V Yu Khripaeva R V Palashkin E A Popova |
| ppnlink |
1760597511 |
| callnumber-subject |
RC - Internal Medicine |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.26442/2075-082X_2018.2.24-31 |
| callnumber-a |
RC666-701 |
| up_date |
2024-07-03T20:15:04.045Z |
| _version_ |
1803590255556689920 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000caa a22002652 4500</leader><controlfield tag="001">DOAJ07143416X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20230309101723.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">230228s2018 xx |||||o 00| ||rus c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.26442/2075-082X_2018.2.24-31</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ07143416X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ99a27042b02c472cb25c448759d04427</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">rus</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RC666-701</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">S V Nedogoda</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Improving blood pressure control, organoprotection and metabolic disorders correction in patients with hypertension switching from diuretic-based combinations to fixed combination lisinopril + amlodipine + rosuvastatin</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2018</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">The aim of the study was to assess the possibility of fixed combination Lisinopril + amlodipine + rozuvastatin to improve arterial elesticity in patients with hypertension and high pulse wave velocity, despite previous diuretic-based combination antihypertensive therapy. Materials and methods. In an open, observational study duration of 24 weeks was included 60 patients on previous diuretic-based combination antihypertensive therapy. All participants underwent 24-hour blood pressure monitoring, applanation tonometry (augmentation index and central blood pressure), pulse wave velocity measurement, laboratory tests (lipid profile, fasting glucose, insulin resistance index - NOMA), leptin, high-sensitivity C-reactive protein before and after the switching to a fixed combination of lisinopril + amlodipine + rosuvastatin. Results. According to measurements of office blood pressure switching of patients on double combinations based on diuretics to a fixed combination of lisinopril + amlodipine + rosuvastatin, a further decrease in systolic blood pressure (SBP) by 13.7% and diastolic BP (DBP) by 18.8% was observed. According to the ABPM, the decline in the average daily SBP was 15.8%, DBP - 22.5%, average SBP - 16.2%, DBP - 19.8%. The combination of lisinopril + amlodipine + rosuvastatin reduced PWV by 15.9%, augmentation index by 13.5%, central SBP by 8.4% (p</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">arterial hypertension</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">pulse wave velocity</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">central blood pressure</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">augmentation index</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">leptin</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">inflammation</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">indapamide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">hydrochlorothiazide</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">lisinopril</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">amlodipine</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">rosuvastatin</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Diseases of the circulatory (Cardiovascular) system</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E V Chumachek</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A A Ledyaeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V V Tsoma</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">A S Salasyuk</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V O Smirnova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">V Yu Khripaeva</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">R V Palashkin</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">E A Popova</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Системные гипертензии</subfield><subfield code="d">IP Morozov P.V., 2018</subfield><subfield code="g">15(2018), 2, Seite 24-31</subfield><subfield code="w">(DE-627)1760597511</subfield><subfield code="x">25422189</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:15</subfield><subfield code="g">year:2018</subfield><subfield code="g">number:2</subfield><subfield code="g">pages:24-31</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.26442/2075-082X_2018.2.24-31</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/99a27042b02c472cb25c448759d04427</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://syst-hypertension.ru/2075-082X/article/viewFile/29600/pdf</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2075-082X</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/2542-2189</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">15</subfield><subfield code="j">2018</subfield><subfield code="e">2</subfield><subfield code="h">24-31</subfield></datafield></record></collection>
|
| score |
7.3993254 |